Lifordi Immunotherapeutics Presents Promising Preclinical Data on Glucocorticoid-Targeting Antibody Drug Conjugate

Lifordi Immunotherapeutics will present additional preclinical data on its lead candidate LFD-200, an antibody drug conjugate delivering a potent glucocorticoid directly to immune cells, at the American College of Rheumatology Convergence 2025 meeting. Results from multiple in vitro and in vivo studies in non-human primates demonstrated that LFD-200 achieves targeted and sustained delivery of its glucocorticoid payload to immune cells without concurrent safety signals, thus providing the efficacy of steroids without systemic toxicity. These findings represent a significant advancement in autoimmune disease treatment, where current steroid therapies often cause widespread side effects due to non-specific systemic exposure.

The new data showed that LFD-200 selectively delivered glucocorticoid to immune tissues and resulted in inhibition of ex vivo induced inflammatory cytokines with no observed systemic toxicity at clinically relevant doses. This targeted approach allows for the anti-inflammatory benefits of glucocorticoids while potentially avoiding the common side effects associated with traditional steroid treatments, such as weight gain, bone density loss, and metabolic disturbances. The sustained delivery mechanism suggests that LFD-200 could require less frequent dosing than current treatment options, improving patient compliance and quality of life.

LFD-200 has demonstrated efficacy in multiple preclinical disease models by targeting myeloid and lymphoid cells using a highly internalized cell surface membrane protein. The antibody drug conjugate platform represents a novel application of ADC technology, traditionally used in oncology, to autoimmune and inflammatory disorders. This approach leverages the precision targeting capabilities of antibodies to deliver potent therapeutic payloads specifically to immune cells involved in disease pathology. The company has applied its novel drug delivery platform to other diverse payloads, including small molecules, antisense oligonucleotides, and siRNA, suggesting broad potential applications across multiple therapeutic areas.

The presentation will occur during the Rheumatoid Arthritis Treatment Poster I session on Sunday, October 26, 2025, at the ACR Convergence meeting in Chicago. These preclinical results support the ongoing Phase 1 clinical trial of LFD-200 and provide important validation of the company's approach to developing targeted therapies for immune-mediated diseases. The ability to deliver glucocorticoids specifically to immune tissues without systemic exposure could revolutionize treatment paradigms for conditions like rheumatoid arthritis, lupus, and other autoimmune disorders where current therapies balance efficacy against significant safety concerns. For more information about the company's research and development programs, visit https://www.lifordi.com.